Patents by Inventor David J. Loury

David J. Loury has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20120100138
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: December 29, 2011
    Publication date: April 26, 2012
    Applicant: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20120087915
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: June 3, 2011
    Publication date: April 12, 2012
    Applicant: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20120065201
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Application
    Filed: September 14, 2011
    Publication date: March 15, 2012
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik J. Verner, Joseph J. Buggy, David J. Loury, Wei Chen
  • BTK INHIBITORS FOR THE TREATMENT OF IMMUNE MEDIATED CONDITIONS
    Publication number: 20120053189
    Abstract: Disclosed herein are pharmaceutical dosage forms of Brutons tyrosine kinase (Btk) inhibitors. Methods for the preparation of the compounds are disclosed. Methods of using the pharmaceutical dosage forms are disclosed for the treatment of immune mediated conditions and inflammatory diseases or conditions.
    Type: Application
    Filed: June 28, 2011
    Publication date: March 1, 2012
    Applicant: Pharmacyclics, Inc.
    Inventor: David J. Loury
  • FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF
    Publication number: 20110311624
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: April 16, 2010
    Publication date: December 22, 2011
    Applicant: PHARMACYCLICS, INC.
    Inventors: David J. LOURY, Joseph J. BUGGY, Tarak D. MODY, Erik J. VERNER, Norbert PURRO, Sriram BALASUBRAMANIAN
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20110086866
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Application
    Filed: October 12, 2010
    Publication date: April 14, 2011
    Applicant: PHARMACYCLICS, INC.
    Inventors: Wei Chen, David J. Loury, Tarak D. Mody, Erik Verner, Mark Stephen Smyth, Wenchen Luo
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20100254905
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Application
    Filed: March 27, 2008
    Publication date: October 7, 2010
    Inventors: Lee Honigberg, Erik J. Verner, Joseph J. Buggy, David J. Loury, Wei Chen
  • Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
    Patent number: 7741330
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: June 22, 2010
    Assignee: Pharmacyclics, Inc.
    Inventors: Wei Chen, David J. Loury, Tarak D. Mody
  • Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
    Patent number: 7718662
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: May 18, 2010
    Assignee: Pharmacyclics, Inc.
    Inventors: Wei Chen, David J. Loury, Tarak D. Mody
  • Water-soluble amide derivatives of polyene macrolides and preparation and uses thereof
    Publication number: 20040138437
    Abstract: The present invention provides two new classes of polyene macrolide amide derivatives useful for treating or preventing fungal infections. The new polyene macrolide amide derivatives exhibit antifungal activity and are more water-soluble than conventional polyene antibiotics, such as amphotericin B and amphotericin B methyl ester.
    Type: Application
    Filed: October 23, 2003
    Publication date: July 15, 2004
    Applicant: Micrologix Biotech Inc.
    Inventors: Conway C. Chang, Binh T. Dang, Christopher J. Baldwin, David J. Loury, Reyna J. Simon, Robert R. Webb
  • Water-soluble amide derivatives of polyene macrolides and preparation and uses thereof
    Patent number: 6664241
    Abstract: The present invention provides two new classes of polyene macrolide amide derivatives useful for treating or preventing fungal infections. The new polyene macrolide amide derivatives exhibit antifungal activity and are more water-soluble than conventional polyene antibiotics, such as amphotericin B and amphotericin B methyl ester.
    Type: Grant
    Filed: May 29, 2001
    Date of Patent: December 16, 2003
    Assignee: Micrologix Biotech Inc.
    Inventors: Conway C. Chang, Binh T. Dang, Christopher J. Baldwin, David J. Loury, Reyna J. Simon, Robert R. Webb
  • Water-soluble amide derivatives of polyene macrolides and preparation and uses thereof
    Publication number: 20030040493
    Abstract: The present invention provides two new classes of polyene macrolide amide derivatives useful for treating or preventing fungal infections. The new polyene macrolide amide derivatives exhibit antifungal activity and are more water-soluble than conventional polyene antibiotics, such as amphotericin B and amphotericin B methyl ester.
    Type: Application
    Filed: May 29, 2001
    Publication date: February 27, 2003
    Inventors: Conway C. Chang, Binh T. Dang, Christopher J. Baldwin, David J. Loury, Reyna J. Simon, Robert R. Webb
  • Compositions and methods for the prevention and treatment of oral mucositis
    Patent number: 6025326
    Abstract: The present invention provides methods and compositions suitable for treating oral mucositis in animals, including humans, with antimicrobial peptides such as protegrin peptides.
    Type: Grant
    Filed: November 21, 1996
    Date of Patent: February 15, 2000
    Assignee: IntraBiotics Pharmaceuticals, Inc.
    Inventors: Deborah A. Steinberg, De Hwa Chao, David J. Loury, Roger Cherng Fu, Chee Liang Gu, Conway C. Chang, John C. Fiddes